Schering-Plough Reports Financial Results for 2007 Fourth Quarter,...(p REMERON c/ 33 - ...)

ZEMURON c/ 25 - N/M 25 - N/M

LIVIAL c/ 24 - N/M 24 - N/M

CERAZETTE c/ 20 - N/M 20 - N/M

MARVELON c/ 20 - N/M 20 - N/M

MERCILON c/ 18 - N/M 18 - N/M

IMPLANON c/ 15 - N/M 15 - N/M

Other

Pharmaceuticals 610 400 53% 1,795 1,609 12%

CONSUMER HEALTH CARE 254 205 24% 1,266 1,123 13%

OTC 161 118 37% 682 558 22%

OTC CLARITIN 94 72 30% 462 390 18%

Foot Care 74 73 1% 345 343 1%

Sun Care 19 14 38% 239 222 8%

ANIMAL HEALTH b/ 507 234 117% 1,251 910 37%

CONSOLIDATED GAAP

NET SALES $3,724 $2,650 41% $12,690 $10,594 20%

a/ Global Pharmaceuticals net sales for both the three and twelve months

ended December 31, 2007, include $409 million from Organon, the human

health business of Organon BioSciences. Sales of Organon are reflected

as of the closing date of the acquisition on November 19, 2007 through

year-end.

b/ Animal Health net sales for both the three and twelve months ended

December 31, 2007, include $217 million from Intervet, the animal

health business of Organon BioSciences. Sales of Intervet are

reflected as of the closing date of the acquisition on November 19,

2007 through year-end.

c/ Products acquired in OBS acquisition reflect net sales for the period

from November 19, 2007 through year-end.

NOTE: Additio
'/>"/>